Abstract
Recent data have shown the efficacy of cetuximab/Folfiri regimen in patients with chemotherapy-resistant metastatic colorectal cancer. In the literature there are no data about this treatment in HIV-positive patients with metastatic colorectal cancer. At the Aviano Cancer Center, we used the cetuximab/Folfiri regimen and concomitant HAART in an HIV-positive patient with metastatic colorectal cancer. The patient experienced acceptable non-hematological toxicity, without any opportunistic infection and his HIV infection was kept under control. This case suggests that, in the HAART era, a multidisciplinary approach can be offered to HIV patients with advanced cancer when they have good performance status, resulting in efficacious control of the HIV infection.
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Antiretroviral Therapy, Highly Active*
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Camptothecin / therapeutic use
-
Cetuximab
-
Colorectal Neoplasms / complications*
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / pathology
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / therapeutic use
-
HIV Infections / complications*
-
HIV Infections / drug therapy*
-
Humans
-
Leucovorin / administration & dosage
-
Leucovorin / therapeutic use
-
Middle Aged
-
Neoplasm Metastasis
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Cetuximab
-
Leucovorin
-
Fluorouracil
-
Camptothecin